Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To start cGMP production for stem cell therapeutic product
Subscribe to our email newsletter
BrainStorm Cell Therapeutics (BrainStorm) has entered into an agreement with Protein Production Services (PPS) in order to start Good Manufacturing Practice (cGMP) production of its stem cell therapeutic product.
Reportedly, the clinical-grade product will be used in a pre-clinical safety trial for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis).
BrainStorm’s proprietary adult stem cell technologies, derived from autologous bone marrow cells, have already been successfully tested on various animal models of neurodegenerative diseases.
Rami Efrati, CEO of BrainStorm, said: “We are very excited that we are moving into this phase of product development with a highly-experienced contractor that will enable us to move rapidly ahead with the final stages of our ALS pre-clinical program.”